Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

PBI4050

Investigational Medicinal Product

DRUG

Placebo

Comparator

Trial Locations (7)

Unknown

St. Paul's Hospital - Pacific Lung Health Centre (PLHC), Vancouver

Queen Elizabeth II Health Science Center, Halifax

Ottawa Hospital Research Institute, Ottawa

St. Michael's Hospital, Toronto

Institut de Recherches Cliniques de Montréal (IRCM), Montreal

Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval (IUCPQ), Québec

Sponsors
All Listed Sponsors
lead

Liminal BioSciences Ltd.

INDUSTRY